< Back to previous page

Project

Use of bispecific AcTakines to boost innate and adaptive immune responses after acute HIV-1 infection

The potential of AcTakines (immunocytokines with reduced binding affinity to decrease systemic side-effects) will be explored as a strategy towards HIV-1 cure. Bispecific IFN-I and IL-1β AcTakines will be constructed, targeting both HIV-infected cells and immune effector cell. They will be tested in vitro on primary cells from early treated HIV+ individuals and in vivo in a humanized mouse model.

Date:15 Nov 2019 →  13 Jan 2024
Keywords:Broadly neutralizing antibodies, Cytokines, HIV-1, Acute HIV-infection
Disciplines:Applied immunology, Compound screening, Virology